David McNally

Chairman, President and CEO

Mr. McNally is the Chairman of the Board of Directors, and President and Chief Executive Officer of Titan Medical Inc. Mr. McNally is an experienced entrepreneur and public company CEO with more than 33 years of experience in the medical device industry...

Throughout his career, Mr. McNally has founded and co-founded start-up companies that commercialized best-in-class surgical, life and organ support, diagnostic and home-care capital equipment, and disposables. Among other accomplishments, he has experience leading companies trading on boards ranging from over-the-counter marketplaces to the Nasdaq exchange. Mr. McNally also has experience in FDA Clearance and CE mark for Class II devices, as well as managing relationships with strategic partners including OEM suppliers and global distributors. Mr. McNally is formerly the founder, President, CEO and Chairman of Domain Surgical Inc., a developer, manufacturer and marketer of advanced energy surgical platforms, which merged with OmniGuide Holdings, Inc. in 2016. Mr. McNally was co-founder, President and CEO of ZEVEX International Inc. (Nasdaq: ZVXI), a developer, manufacturer and marketer of award-winning medical devices, which was acquired by MOOG Inc. in 2007. Mr. McNally earned an MBA from the University of Utah, holds a Bachelor of Science degree in Mechanical Engineering from Lafayette College, Easton, PA and is the co-inventor of more than 40 U.S. and international patents associated with robotic surgical systems, ferromagnetic surgical devices and systems, electromagnetic and ultrasonic sensors, and medical fluid delivery systems.

Monique L. Delorme

Chief Financial Officer

Ms. Delorme joined Titan Medical in March 2019 as Vice President, Finance and was named Chief Financial Officer in September 2020. She has more than 25 years of senior corporate leadership experience in the areas of finance, operations, corporate strategy and change management. She has served as a financial executive for several large and small publicly traded companies where she earned a reputation as a strategic leader with strong execution and communication skills...

In 2012, she launched a successful consulting practice providing financial and CFO services to both private and public companies. Ms. Delorme is a Certified Public Accountant and a graduate of McGill University.

Perry Genova, PhD

Senior Vice President, Research and Development, and President of Titan Medical USA Inc.

Dr. Genova is an accomplished, innovative, and seasoned executive who, over a career spanning 30 years, has been recognized for building and leading successful teams in both small and multi-national companies. He has led four medical device startup companies and has broad expertise across pharmaceutical, medical device, and consumer product industries...

He received PhD and Master of Science degrees in Biomedical Engineering from the University of North Carolina (UNC) at Chapel Hill and a Bachelor of Science degree in Electrical Engineering from UNC Charlotte. Dr. Genova is a co-inventor on 55 issued and pending U.S. patents and co-author of over 30 scientific papers and presentations.

Curtis Jensen

Vice President, Quality and Regulatory Affairs

Mr. Jensen has more than 20 years of experience leading successful quality and regulatory affairs teams at several U.S. companies. Prior to joining Titan, he served since 2015 as Senior Regulatory Affairs Associate at EKOS, a privately held medical equipment manufacturer. There, he was responsible for worldwide regulatory approval for a new CU 4.0 Control System for an ultrasound pulmonary embolism catheter...

Prior to EKOS, he held multiple positions at Domain Surgical Inc., a manufacturer of advanced thermal surgical instruments, including serving as Vice President of Quality and Regulatory Affairs. Mr. Jensen holds a Master of Science degree in Applied Mathematics from Johns Hopkins University and a Bachelor of Science degree in Electrical Engineering from Utah State University.

Jasminder Brar

Vice President, Legal, IP and Strategic Initiatives, General Counsel

Mr. Brar draws from more than 15 years of technical, business and legal experience to manage Titan’s legal affairs while leading and executing a comprehensive IP program that facilitates innovation, enhances business objectives and mitigates risks. Working alongside other Titan executives, engineering teams and advisers, Mr. Brar ensures that the company’s IP strategy remains in alignment with – and continues to influence and enhance – the company’s overall business strategy...

Before joining Titan, Mr. Brar practiced with the law firm of Smart & Biggar in Vancouver, British Columbia… Before practicing law, he worked as an engineer and in product marketing with National Semiconductor in Santa Clara, California. Mr. Brar is deeply passionate about innovation that enhances people’s quality of life and the role of intellectual property in driving, supporting and testing such innovation. He has a Law degree (LL.B.) and a Bachelor of Science degree in Computer Engineering, both from the University of Manitoba.

Chris Seibert

Vice President, Upstream Marketing

Mr. Seibert has 16+ years of experience in the medical device industry, spanning clinical sales, sales leadership, strategic planning and product development at companies ranging from those with a very mature product lifecycle to early stage, pre-submission products...

Mr. Seibert has spent 15 years focusing on robotic medical devices, including stints of increasing levels of responsibility at both Intuitive Surgical, Inc., and Stereotaxis, Inc. Mr. Seibert has an in-depth, national network of innovative physicians and healthcare executives. He has worked for four start-up companies and has extensive relationships across the IDN/GPO landscape. Mr. Seibert has a Bachelor of Arts from the University of Alabama, a Master of Arts in Human Relations from the University of Oklahoma and an MBA from the University of South Alabama.

Kristen Galfetti

Vice President, Investor Relations Corporate Communications

Ms. Galfetti has over 20 years of experience leading investor relations and corporate communications programs. Most recently, Ms. Galfetti provided consulting services to small and medium companies in the life science industries.

Her corporate experience includes serving as Vice President, Investor Relations & Corporate Communications at Cynapsus Therapeutics. Prior to Cynapsus, she was Senior Director, Investor Relations at Sanofi, responsible for integrating the Genzyme Corporation investor relations program post-merger. Prior to Sanofi, Ms. Galfetti was Senior Director, Corporate Communications and Investor Relations at AMAG Pharmaceuticals. Prior to AMAG, Ms. Galfetti held Investor Relations roles of increasing responsibility at Genzyme Corporation. Ms. Galfetti holds a Bachelor of Arts in Political Science from the University of Vermont and a Master of Business Administration (with distinction) from Bentley University.

Chien Huang

Vice President, Finance 

Mr. Huang is a financial executive with over 20 years of experience developing and implementing financial models and systems, and accounting practices to support the achievement of strategic corporate objectives.

Mr. Huang has strong expertise in evaluating investment opportunities and long-term value creation as well as extensive knowledge of IFRS and U.S. GAAP reporting requirements. Most recently, he served as Senior Vice President, Corporate Finance at Quarterhill Inc., where he led the finance systems migration and reorganized key business processes, streamlining external reporting processes. Prior to Quarterhill, Mr. Huang served as Vice President, Finance at Aralez Pharmaceuticals, responsible for implementing systems upgrades, negotiating potential divestitures and advising on private equity financing. Prior to this, Mr. Huang was Senior Director, Finance at Astellas Pharma. Mr. Huang holds a Bachelor of Science in Physiology from the University of Toronto, a Graduate Diploma in Public Accountancy from McGill University, and has Chartered Accountant Designation.